Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603120 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 567
- Enrollment target
NCT02603120 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 567 participants.
The verdict
NCT02603120, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 567 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.
Interventions
- DRUG B/F/TAF
- DRUG ABC/DTG/3TC
- DRUG ABC/DTG/3TC Placebo
- DRUG B/F/TAF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 567 participants |
| Start Date | 2015-11-11 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603120
The ClinicalTrials.gov registry entry for NCT02603120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 567 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which B/F/TAF is the first listed.
NCT02603120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603120 about?
NCT02603120 is a clinical study titled "Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed". The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF...
What is the current status of trial NCT02603120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 567 participants. The study started on 2015-11-11. Estimated completion is 2019-10-23.
What interventions are being tested in trial NCT02603120?
The interventions under investigation include: B/F/TAF (DRUG), ABC/DTG/3TC (DRUG), ABC/DTG/3TC Placebo (DRUG), B/F/TAF Placebo (DRUG).
Who is sponsoring clinical trial NCT02603120?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.